Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 9/20 | 1.00 |
| ▸ | CNR2 | P34972 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29426346 | 0.89 | CNR2 (1.00) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL8932684 | 0.88 | CNR2 (0.77) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL8932641 | 0.87 | CNR2 (0.83) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL9090895 | 0.87 | CNR2 (0.77) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL9089488 | 0.78 | CNR2 (0.78) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL8932689 | 0.78 | CNR2 (0.64) | CNR1CNR2 | |
| SCHEMBL9088862 | 0.77 | CNR2 (0.87) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL10669175 | 0.75 | CNR1 (1.00) | CNR1CNR2 | |
| SCHEMBL8932634 | 0.74 | CNR2 (0.88) | CNR1CNR2SMN1; SMN2 | |
| SCHEMBL8932661 | 0.74 | CNR2 (1.00) | CNR1CNR2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-1996025397-A1 | INDOLE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID RECEPTOR | MERCK FROSST CANADA INC. (CA) | 1996-08-22 | — | — | WO | claimed |
| US-5532237-A | INTRAOCULAR FOR TREATMENT OF GLAUCOMA | MERCK FROSST CANADA, INC. (CA) | 1996-07-02 | — | — | US | claimed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| WO-1996025397-A1 | INDOLE DERIVATIVES WITH AFFINITY FOR THE CANNABINOID RECEPTOR | MERCK FROSST CANADA INC. (CA) | 1996-08-22 | — | — | WO | disclosed |
| US-5532237-A | INTRAOCULAR FOR TREATMENT OF GLAUCOMA | MERCK FROSST CANADA, INC. (CA) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | CNR1 1/4885CNR2 2/4885KDM4E 3245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.